Actively Recruiting
Fatty Liver Library FALL a Prospective Cohort Study Evaluating the Characteristics of Chronic Liver Diseases Associated With Hepatic Steatosis
Led by University of Copenhagen · Updated on 2022-04-19
335
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
Sponsors
U
University of Copenhagen
Lead Sponsor
H
Hvidovre University Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are evaluating patients with chronic liver diseases linked to hepatic steatosis, a condition where fat accumulation in the liver may cause inflammation and scarring. This condition can lead to serious liver problems such as cirrhosis, liver failure, and death. The study aims to better understand the underlying mechanisms of these diseases and to identify specific diagnostic markers and potential future treatments by examining tissue-level characteristics. This observational study involves collecting detailed biological samples and data from adults with various chronic liver diseases, including autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis, hereditary hemochromatosis, alpha-1-antitrypsin deficiency, and others. The study does not involve any drug or device interventions but focuses on in-depth phenotyping and metabolic assessments at multiple time points. Participants will be observed and evaluated over a period of up to 10 years. Researchers will collect plasma samples at several intervals and aim to identify diagnostic classifiers to distinguish between different chronic liver diseases. The study includes regular assessments and long-term monitoring to gather comprehensive data on metabolic disturbances and disease characteristics. Participation involves informed consent and adherence to scheduled evaluations without treatment administration.
CONDITIONS
Brief Title
An Observational Study Evaluating Patients With Chronic Liver Diseases Associated With Hepatic Steatosis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult patients or healthy control participants aged 18 or older who can give informed consent
- Suspected liver disease including non-alcoholic steatohepatitis
- Alcoholic steatohepatitis
- Autoimmune hepatitis
- Primary biliary cholangitis
- Primary sclerosing cholangitis
- Inflammatory bowel disease
- Polycystic ovary syndrome
- Hereditary haemochromatosis
- Chronic pancreatitis
- Cystic fibrosis
- Alpha-1 antitrypsin deficiency
You will not qualify if you...
- Patients with malignant diseases
- Patients with viral hepatitis
- Patients with human immunodeficiency virus
- Patients with contraindications to liver biopsy
Research Team
A
Anne-Sofie H Jensen, MD
L
Lise L Gluud, Professor
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here